Fairmount Funds Management LLC is an investment firm that reports beneficial ownership of shares in Apogee Therapeutics, Inc. (APGE) and 9 other companies under U.S. securities law. It has submitted 24 SEC insider filings since 2024, most recently in August 2026.
Every role Fairmount Funds Management LLC has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Apogee Therapeutics, Inc. (APGE)2 filingsCRESCENT BIOPHARMA, INC. (CBIO)2 filingsOruka Therapeutics, Inc. (ORKA)2 filingsSpyre Therapeutics, Inc. (SYRE)1 filingJade Biosciences, Inc. (JBIO)1 filingUpdated Aug 30, 2026
Fairmount Funds Management LLC is Director of Apogee Therapeutics, Inc. (APGE). 24 SEC Form 4 filings on record going back to 2024, most recently on 11 August 2026. Most recent open-market trade: bought $12.38M of CBIO on 20 July 2026. Lifetime open-market purchases: $84.01M. Lifetime open-market sales: $1.20B. Historical track record: 3/5 stars across 5 tracked purchases.
Every recent SEC Form 4 transaction Fairmount Funds Management LLC has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★☆☆ (3/5) |
| Total purchases tracked | 5 |
| Purchases with forward-return data | 5 |
| 30-day win rate | 60% |
| 90-day win rate | 80% |
| Avg 5-day return | +9.15% |
| Avg 30-day return | +18.41% |
| Avg 90-day return | +26.87% |
| Best 30-day return |
InsiderAlpha's records for Fairmount Funds Management LLC go back to 2024: 24 primary Form 4 filings, an average of 8.0 per year. The typical open-market purchase is $12.00M (7 buys totaling $84.01M). The largest single buy on record is $25.00M of COGT in 2025. Sales side: 5 recorded sales totaling $1.20B, so the filing history runs sell-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Fairmount Funds Management LLC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Fairmount Funds Management LLC is an investment firm, tracked as Director of Apogee Therapeutics, Inc. (APGE). InsiderAlpha holds 24 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
8 primary Form 4 filings in the last 90 days, covering 5 companies.
Recorded transactions: 7 open-market purchases ($84.01M) and 5 open-market sales ($1.20B) across all tracked filings.
Across 5 tracked purchases, Fairmount Funds Management LLC averaged +18.4% avg 30-day return with a 60% 30-day win rate. InsiderAlpha rates the track record at 3/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$CBIO CRESCENT BIOPHARMA, INC.853.5K shares @ $14.50$12.38M
| +55.68% |